In vitro evidence for an intracellular site of angiotensin action.
To differentiate the relative effects of nuclear and cell surface angiotensin II (Ang II) receptors, we mutated the angiotensinogen cDNA by removing the signal sequence-encoding region to produce a nonsecreted form of angiotensinogen [Ang(-S)Exp]. Rat hepatoma cells (which produce renin and angiotensin-converting enzyme mRNAs) were stably transfected with Ang(-S)Exp/pSVL (or a corresponding control) expression plasmid, and mitotic indices were measured for stably transfected cell lines. Experimental clonal cell lines demonstrate an average of 33+/-4.4% (P<0.001) increase in percentage-labeled nuclei compared with control cell lines. The mitogenic effect is blocked by 10(-6) mol/L losartan and by 1 micromol/L renin antisense phosphorothioate oligomers but not by 10(-6) mol/L candesartan. In addition, phenylarsine oxide, which blocks angiotensin receptor internalization, abolishes the losartan inhibitory effect, suggesting that after cell-surface receptor-mediated endocytosis, losartan blocks Ang II nuclear receptors. PDGF mRNA levels are elevated 2.2-fold in Ang(-S)Exp transfected cell lines; addition of anti-PDGF antibodies to the culture medium partially blocks the mitogenic effect of Ang(-S)Exp, while anti-Ang II antibodies have no effect. These results suggest that the Ang(-S)Exp growth effect is due, in part, to autocrine/paracrine stimulation by secreted PDGF after Ang II/Ang II receptor intracellular interactions. We further demonstrate that these cells produce the alternative renin transcript, renin 1A, which apparently lacks a signal sequence and is maintained intracellularly. Collectively, these studies of cultured cells suggest that some cell types may possess components of the renin-angiotensin system that permit intracellular processing of angiotensinogen to Ang II and that Ang II generated intracellularly may be mitogenic.
Cook
J L
JL
Division of Research, Ochsner Clinic Foundation, New Orleans, LA, USA. jcook@ochsner.org
Zhang
Z
Z
Re
R N
RN
D017398:Alternative Splicing; D057911:Angiotensin Receptor Antagonists; D000808:Angiotensinogen / Q000235:genetics / Q000378:metabolism; D000809:Angiotensins / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001562:Benzimidazoles / Q000494:pharmacology; D001713:Biphenyl Compounds; D001973:Bromodeoxyuridine; D006528:Carcinoma, Hepatocellular / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects / Q000235:genetics; D002999:Clone Cells / Q000378:metabolism; D007424:Intracellular Fluid / Q000378:metabolism*; D019808:Losartan / Q000494:pharmacology; D008940:Mitotic Index; D016297:Mutagenesis, Site-Directed; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D007703:Peptidyl-Dipeptidase A / Q000096:biosynthesis; D016133:Polymerase Chain Reaction; D051381:Rats; D011945:Receptors, Angiotensin / Q000378:metabolism*; D018160:Receptors, Cytoplasmic and Nuclear / Q000037:antagonists & inhibitors / Q000378:metabolism; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D012083:Renin / Q000096:biosynthesis / Q000235:genetics; D017384:Sequence Deletion; D013777:Tetrazoles / Q000494:pharmacology; D014162:Transfection; D014407:Tumor Cells, Cultured; D000092502:Renin Inhibitors
D057911:Angiotensin Receptor Antagonists; D000808:Angiotensinogen; D000809:Angiotensins; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D001973:Bromodeoxyuridine; D019808:Losartan; D016376:Oligonucleotides, Antisense; D007703:Peptidyl-Dipeptidase A; D011945:Receptors, Angiotensin; D018160:Receptors, Cytoplasmic and Nuclear; D011994:Recombinant Proteins; D012083:Renin; D013777:Tetrazoles; D000092502:Renin Inhibitors; C081643:candesartan